| Articles | September 1, 2003
Epidemiology and Risk Factors Prostate cancer is the most common nonskin malignancy among men in Europe, North America, and Australia and, after lung cancer, represents the second leading cause of cancer-related death in men in these regions.4 Data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, which covers approximately 26% of the US population, show the rising incidence of cancer of the prostate (Figure 1).
Newsletter Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Subscribe
September 18th, 2026 Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
September 18th, 2026 The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
September 18th, 2026 A decision is expected by the fourth quarter of 2026.
September 17th, 2026 Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
September 17th, 2026 Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
September 17th, 2026 EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
September 17th, 2026 Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
September 16th, 2026 The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.